← FDA DRUG APPROVALS

FDA NDA · NDA050809

AZITHROMYCIN

Sponsor: TEVA PARENTERAL

APPLICATION
NDA050809
TYPE
NDA
ORIGINAL APPROVAL
2006-12-19
LATEST ACTION
2006-12-19
ROUTE
INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Discontinued

Products

AZITHROMYCINDiscontinued
AZITHROMYCIN EQ 2.5GM BASE/VIAL · INJECTABLE · INJECTION
AZITHROMYCINDiscontinued
AZITHROMYCIN EQ 500MG BASE/VIAL · INJECTABLE · INJECTION

Approval history

2006-12-19Type 3 - New Dosage Form · Original · standard — Label ↗AP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industry →GMP discipline →FDA drug shortages →FDA enforcement & recalls →

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →